Quick Answer
Kairos Pharma, LTD. reported Stockholders Equity of $6.34 million for the year ending 2025.
- Kairos Pharma, LTD. showed an increase of +32.8% in Stockholders Equity from 2024 to 2025.
- This data is from Kairos Pharma, LTD.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: -$1.56 million | Q3 2023: -$1.87 million | Q1 2024: -$2.40 million | Q2 2024: -$2.65 million | Q3 2024: $3.33 million | Q1 2025: $7.13 million | Q2 2025: $6.00 million | Q3 2025: $7.66 million.
- Over the full 4 years of available data (2022 to 2025), Kairos Pharma, LTD.'s Stockholders Equity has grown by 637.8%.
- Historical annual values: Fiscal year 2025: $6.34 million | Fiscal year 2024: $4.78 million | Fiscal year 2023: -$2.08 million | Fiscal year 2022: -$1.18 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: